



Clinical trial results:

A Randomised, Double-Blind, Vehicle-Controlled Phase 2 Study of Topically Applied INM-755 (cannabinol) Cream in Patients with Epidermolysis Bullosa.

Summary

| | |
|--------------------------|-------------------|
| EudraCT number | 2021-000214-42 |
| Trial protocol | DE FR AT GR IT ES |
| Global end of trial date | 19 April 2023 |

Results information

| | |
|--------------------------------|---------------|
| Result version number | v1 (current) |
| This version publication date | 13 April 2024 |
| First version publication date | 13 April 2024 |

Trial information

Trial identification

| | |
|-----------------------|------------|
| Sponsor protocol code | 755-201-EB |
|-----------------------|------------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT04908215 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | InMed Pharmaceuticals Inc. |
| Sponsor organisation address | Suite 310 - 815 West Hastings Street, Vancouver, Canada, V6C 1B4 |
| Public contact | Clinical Research Executive, InMed Pharmaceuticals Inc., 1 604-669-7207, clinical@inmedpharma.com |
| Scientific contact | Clinical Research Executive, InMed Pharmaceuticals Inc., 1 604-669-7207, clinical@inmedpharma.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|---------------|
| Analysis stage | Final |
| Date of interim/final analysis | 19 April 2023 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 19 April 2023 |
| Global end of trial reached? | Yes |
| Global end of trial date | 19 April 2023 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

- To evaluate the safety of INM-755 cream in patients with EB.
- To obtain preliminary evidence of efficacy of INM-755 cream on wound and non-wound affected skin areas in patients with EB.

Protection of trial subjects:

No special measures were required for this Phase 2 study of a topical cream product. If an important adverse reaction to the cream were to occur, it would simply be washed off and/or not re-applied in accordance with normal investigator oversight and patient preference.

Background therapy: -

Evidence for comparator: -

| | |
|---|------------------|
| Actual start date of recruitment | 15 December 2021 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|------------|
| Country: Number of subjects enrolled | Germany: 3 |
| Country: Number of subjects enrolled | Greece: 5 |
| Country: Number of subjects enrolled | Italy: 4 |
| Country: Number of subjects enrolled | Israel: 2 |
| Country: Number of subjects enrolled | France: 5 |
| Worldwide total number of subjects | 19 |
| EEA total number of subjects | 17 |

Notes:

Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 3 |

| | |
|----------------------|----|
| Adults (18-64 years) | 15 |
| From 65 to 84 years | 1 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

Recruitment of patients for this very rare disease was undertaken in 6 EU countries (Austria, France, Germany, Greece, Italy, and Spain) and Israel. No patients were enrolled in Austria or Spain. The first patient was screened on 15Dec2021 in Israel and enrolled (first treatment) on 28Dec2021. The last patient was enrolled 10Mar2023.

Pre-assignment

Screening details:

Overall 27 subjects were screened: 4 subjects were screen failures immediately, 4 were SFs at the end of baseline observation week. A total of 19 patients were enrolled and received INM-755 cream and Vehicle cream. This study used a within-patient randomisation of pairs of matched index areas (1 area to INM-755 therapy and 1 area to Vehicle cream).

Period 1

| | |
|------------------------------|---|
| Period 1 title | Treatment Period (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator, Monitor, Carer, Assessor |

Blinding implementation details:

Each patient could have a matched pair of non-wound index areas, wound index areas, or both. Each index area in a matched pair was randomised to INM-755 cream or Vehicle cream in a 1:1 ratio in a blinded manner. Study creams were identical in appearance and labelled in a blinded way. No study site personnel, patient, Sponsor personnel, or Sponsor designee who was involved in study conduct decisions was unblinded to treatment assignment throughout the duration of the study.

Arms

| | |
|------------------------------|-------------------|
| Are arms mutually exclusive? | No |
| Arm title | Non-Wound INM-755 |

Arm description:

Non-wound index area within a matched pair assigned to INM-755 treatment

| | |
|--|----------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | INM-755 (cannabinol) Cream |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Cream |
| Routes of administration | Cutaneous use, Topical |

Dosage and administration details:

For non-wound index areas, the application of the study drug (either INM-755 cream or Vehicle cream) was done once daily, applied by the patient or caregiver directly on the index area skin in a typical thin layer (approximately 2 mg cream per cm² of skin) and gently rubbed into the skin. Patients were given practical instructions on how to measure a suitable amount of cream using Fingertip Units calculated for the size of the area being treated. No dressing was required, but it was optional per the patient's preference. Treatment was to be given for a maximum of 28 days (Days 1 to 28).

| | |
|------------------|-------------------|
| Arm title | Non-Wound Vehicle |
|------------------|-------------------|

Arm description:

Non-wound index area within a matched pair assigned to Vehicle control treatment

| | |
|----------|-----------------|
| Arm type | vehicle control |
|----------|-----------------|

| | |
|--|------------------------|
| Investigational medicinal product name | Vehicle Cream |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Cream |
| Routes of administration | Cutaneous use, Topical |

Dosage and administration details:

For non-wound index areas, the application of the study drug (either INM-755 cream or Vehicle cream) was done once daily, applied by the patient or caregiver directly on the index area skin in a typical thin layer (approximately 2 mg cream per cm² of skin) and gently rubbed into the skin. Patients were given practical instructions on how to measure a suitable amount of cream using Fingertip Units calculated for the size of the area being treated. No dressing was required, but it was optional per the patient's preference. Treatment was to be given for a maximum of 28 days (Days 1 to 28).

| Number of subjects in period 1 | Non-Wound INM-755 | Non-Wound Vehicle |
|---------------------------------------|-------------------|-------------------|
| Started | 18 | 18 |
| Week 1 | 18 | 18 |
| Week 2 | 18 | 18 |
| Week 3 | 18 | 18 |
| Week 4 | 17 | 17 |
| Completed | 17 | 17 |
| Not completed | 1 | 1 |
| Adverse event, non-fatal | 1 | 1 |

Baseline characteristics

Reporting groups

| Reporting group title | Treatment Period |
|--|------------------|
| Reporting group description: | |
| 19 patients were enrolled and treated. Each patient had at least one pair of matched index areas treated with INM-755 and Vehicle in a randomized blinded manner. 17 patients had 1 pair of matched non-wound (NW) Index areas. 1 patient had 1 pair of matched wound (W) Index areas. 1 patient had both 1 pair of NW index areas and 1 pair of W index areas. N=18 patients for NW index areas, N=2 for W index areas. | |

| Reporting group values | Treatment Period | Total | |
|---|------------------|-------|--|
| Number of subjects | 19 | 19 | |
| Age categorical | | | |
| Units: Subjects | | | |
| Adolescents (12-17 years) | 3 | 3 | |
| Adults (18-64 years) | 15 | 15 | |
| From 65-84 years | 1 | 1 | |
| Age continuous | | | |
| Units: years | | | |
| arithmetic mean | 35.3 | | |
| standard deviation | ± 15.39 | - | |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 11 | 11 | |
| Male | 8 | 8 | |
| Race | | | |
| Units: Subjects | | | |
| White | 19 | 19 | |
| Ethnicity | | | |
| Units: Subjects | | | |
| Hispanic or Latino | 0 | 0 | |
| Not Hispanic or Latino | 16 | 16 | |
| Unknown/Not Reported | 3 | 3 | |
| Fitzpatrick Skin Type | | | |
| Skin Type scale based on skin colour and sensitivity to sun | | | |
| Units: Subjects | | | |
| Fitzpatrick Skin Type I | 2 | 2 | |
| Fitzpatrick Skin Type II | 6 | 6 | |
| Fitzpatrick Skin Type III | 10 | 10 | |
| Fitzpatrick Skin Type IV | 1 | 1 | |
| Fitzpatrick Skin Type V | 0 | 0 | |
| Fitzpatrick Skin Type VI | 0 | 0 | |
| Epidermolysis bullosa (EB) Type | | | |
| Genetic subtype of epidermolysis bullosa | | | |
| Units: Subjects | | | |
| EB Simplex | 4 | 4 | |
| EB Junctional | 2 | 2 | |
| EB Dominant Dystrophic | 2 | 2 | |
| EB Recessive Dystrophic | 9 | 9 | |

| | | | |
|------------|---|---|--|
| EB Kindler | 2 | 2 | |
|------------|---|---|--|

Subject analysis sets

| | |
|----------------------------|---------------------------|
| Subject analysis set title | Safety Analysis Set (SAF) |
| Subject analysis set type | Safety analysis |

Subject analysis set description:

The SAF consisted of all index areas (non-wound or wound) that received INM-755 cream or matching Vehicle cream. The SAF was used for safety summaries and analysis of local effects. All patients who received the study drug were assessed for systemic effects.

A total of 19 patients were enrolled and treated; 18 patients had non-wound index pairs and 2 patients had wound index pairs. One of the 19 patients had both non-wound and wound index pairs. Within each index pair, one skin area was randomized to INM-755 and one was randomized to Vehicle, in a blinded manner.

| | |
|----------------------------|------------------------------------|
| Subject analysis set title | Pharmacokinetic Analysis Set (PKS) |
| Subject analysis set type | Safety analysis |

Subject analysis set description:

The PKS included all patients who received at least one dose of the study drug and had at least one PK concentration measured.

Provision of a single blood sample at the end of treatment for measurement of plasma cannabiniol concentration was optional and 14 patients consented for that procedure.

| | |
|----------------------------|---|
| Subject analysis set title | Non-wound Itch Evaluable Analysis Set (ESA) |
| Subject analysis set type | Per protocol |

Subject analysis set description:

All non-wound index areas meeting the eligibility criterion of non-wound itch ≥ 40 mm on Visual Analogue Scale (VAS, 0-100 mm) during the Baseline Observation Period (1 week before randomization and treatment initiation).

*If a randomisation error was detected after database lock (once unblinding had occurred) then the SAF analysis set was to be used, in order to consider the effect of the actual treatment. This is what was done. It was an analysis "as treated".

| Reporting group values | Safety Analysis Set (SAF) | Pharmacokinetic Analysis Set (PKS) | Non-wound Itch Evaluable Analysis Set (ESA) |
|---|---------------------------|------------------------------------|---|
| Number of subjects | 19 | 14 | 14 |
| Age categorical Units: Subjects | | | |
| Adolescents (12-17 years) | 3 | 0 | 2 |
| Adults (18-64 years) | 15 | 13 | 11 |
| From 65-84 years | 1 | 1 | 1 |
| Age continuous Units: years arithmetic mean standard deviation | \pm | \pm | \pm |
| Gender categorical Units: Subjects | | | |
| Female | 11 | 6 | 9 |
| Male | 8 | 8 | 5 |
| Race Units: Subjects | | | |
| White | 19 | 14 | 14 |
| Ethnicity | | | |

| | | | |
|---|----|----|----|
| Units: Subjects | | | |
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 16 | 11 | 13 |
| Unknown/Not Reported | 3 | 3 | 1 |
| Fitzpatrick Skin Type | | | |
| Skin Type scale based on skin colour and sensitivity to sun | | | |
| Units: Subjects | | | |
| Fitzpatrick Skin Type I | 2 | 1 | 2 |
| Fitzpatrick Skin Type II | 6 | 5 | 3 |
| Fitzpatrick Skin Type III | 10 | 7 | 8 |
| Fitzpatrick Skin Type IV | 1 | 1 | 1 |
| Fitzpatrick Skin Type V | 0 | 0 | 0 |
| Fitzpatrick Skin Type VI | 0 | 0 | 0 |
| Epidermolysis bullosa (EB) Type | | | |
| Genetic subtype of epidermolysis bullosa | | | |
| Units: Subjects | | | |
| EB Simplex | 4 | 2 | 3 |
| EB Junctional | 2 | 2 | 0 |
| EB Dominant Dystrophic | 2 | 2 | 2 |
| EB Recessive Dystrophic | 9 | 6 | 7 |
| EB Kindler | 2 | 2 | 2 |

End points

End points reporting groups

| | |
|-----------------------|-------------------|
| Reporting group title | Non-Wound INM-755 |
|-----------------------|-------------------|

Reporting group description:

Non-wound index area within a matched pair assigned to INM-755 treatment

| | |
|-----------------------|-------------------|
| Reporting group title | Non-Wound Vehicle |
|-----------------------|-------------------|

Reporting group description:

Non-wound index area within a matched pair assigned to Vehicle control treatment

| | |
|----------------------------|---------------------------|
| Subject analysis set title | Safety Analysis Set (SAF) |
|----------------------------|---------------------------|

| | |
|---------------------------|-----------------|
| Subject analysis set type | Safety analysis |
|---------------------------|-----------------|

Subject analysis set description:

The SAF consisted of all index areas (non-wound or wound) that received INM-755 cream or matching Vehicle cream. The SAF was used for safety summaries and analysis of local effects. All patients who received the study drug were assessed for systemic effects.

A total of 19 patients were enrolled and treated; 18 patients had non-wound index pairs and 2 patients had wound index pairs. One of the 19 patients had both non-wound and wound index pairs. Within each index pair, one skin area was randomized to INM-755 and one was randomized to Vehicle, in a blinded manner.

| | |
|----------------------------|------------------------------------|
| Subject analysis set title | Pharmacokinetic Analysis Set (PKS) |
|----------------------------|------------------------------------|

| | |
|---------------------------|-----------------|
| Subject analysis set type | Safety analysis |
|---------------------------|-----------------|

Subject analysis set description:

The PKS included all patients who received at least one dose of the study drug and had at least one PK concentration measured.

Provision of a single blood sample at the end of treatment for measurement of plasma cannabiniol concentration was optional and 14 patients consented for that procedure.

| | |
|----------------------------|---|
| Subject analysis set title | Non-wound Itch Evaluable Analysis Set (ESA) |
|----------------------------|---|

| | |
|---------------------------|--------------|
| Subject analysis set type | Per protocol |
|---------------------------|--------------|

Subject analysis set description:

All non-wound index areas meeting the eligibility criterion of non-wound itch ≥ 40 mm on Visual Analogue Scale (VAS, 0-100 mm) during the Baseline Observation Period (1 week before randomization and treatment initiation).

*If a randomisation error was detected after database lock (once unblinding had occurred) then the SAF analysis set was to be used, in order to consider the effect of the actual treatment. This is what was done. It was an analysis "as treated".

Primary: NW Itch: Within-patient difference in CFB (INM-755 - Vehicle)

| | |
|-----------------|---|
| End point title | NW Itch: Within-patient difference in CFB (INM-755 - Vehicle) |
|-----------------|---|

End point description:

Patients scored itch once daily for each non-wound (NW) index area within a matched pair (one area received INM-755, the other received Vehicle, as randomized and blinded). Itch was scored on the Visual Analogue Scale (0-100 mm), with 0 score meaning no itch and 100 score meaning the worst imaginable itch. Average weekly Itch scores were calculated for each index area and within-patient comparisons of INM-755 and Vehicle were tested using paired t-tests of the Change from Baseline (CFB). Note for interpretation: A negative value for within-patient difference in CFB (INM-755 - Vehicle) would favour INM-755.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Weekly for 4 weeks

| End point values | Non-Wound INM-755 | Non-Wound Vehicle | Non-wound Itch Evaluable Analysis Set (ESA) | |
|--------------------------------------|---------------------|---------------------|---|--|
| Subject group type | Reporting group | Reporting group | Subject analysis set | |
| Number of subjects analysed | 14 ^[1] | 14 ^[2] | 14 ^[3] | |
| Units: mm | | | | |
| arithmetic mean (standard deviation) | | | | |
| Week 1 | -19.224 (± 27.2640) | -17.786 (± 18.9561) | -1.439 (± 15.8467) | |
| Week 2 | -19.306 (± 27.3566) | -20.194 (± 24.9994) | 0.888 (± 7.6389) | |
| Week 3 | -23.19 (± 23.9680) | -23.614 (± 24.8766) | 0.424 (± 15.6356) | |
| Week 4 | -32.021 (± 26.6676) | -29.867 (± 26.8017) | -2.155 (± 14.3983) | |

Notes:

[1] - NW index areas excluded from ESA for 4 pts; 1 patient missing Week 4

[2] - NW index areas excluded from ESA for 4 pts; 1 patient missing Week 4

[3] - The within-patient difference in CFB for matched index areas (INM-755 - Vehicle). 1 missing Wk 4.

Statistical analyses

| | |
|---|---|
| Statistical analysis title | NW Itch: Within-patient Paired t-test, Week 4 |
| Statistical analysis description: | |
| Average weekly Itch scores were calculated for each index area and within-patient comparisons of INM-755 and Vehicle were tested using paired t-tests of the Change from Baseline (CFB). A negative value for within-patient difference in CFB (INM-755 - Vehicle) favours INM-755. | |
| Comparison groups | Non-Wound INM-755 v Non-Wound Vehicle |
| Number of subjects included in analysis | 28 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.5994 ^[4] |
| Method | paired t-test |
| Parameter estimate | Mean difference (final values) |
| Point estimate | -2.155 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -10.8554 |
| upper limit | 6.5462 |
| Variability estimate | Standard deviation |
| Dispersion value | 14.3983 |

Notes:

[4] - p-values at earlier timepoints:

Week 1 = 0.7395

Week 2 = 0.6708

Week 3 = 0.9206

Secondary: PIC-I: Within-patient difference in CFB (INM-755 - Vehicle)

| | |
|-----------------|---|
| End point title | PIC-I: Within-patient difference in CFB (INM-755 - Vehicle) |
|-----------------|---|

End point description:

PIC-I = Patient's Impression of Change for Non-wound Itch. This was reported by the patient after 2 and 4 weeks of treatment for each of the matched index areas (one treated with INM-755, one with Vehicle). They scored their impression of change from baseline, using the Dynamic Pruritus Scale (+50 mm for maximal improvement (almost no itch remaining) to -50 mm (maximal worsening of itch), with 0 mm for no change. Note for interpretation: A positive result for within patient difference (PIC-I INM-755

minus PIC-I Vehicle) would indicate a better outcome on itch for INM-755 compared with Vehicle on the basis of PIC-I.

| | |
|----------------------|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Week 2 and Week 4 | |

| End point values | Non-Wound INM-755 | Non-Wound Vehicle | Non-wound Itch Evaluable Analysis Set (ESA) | |
|--------------------------------------|-------------------|-------------------|---|--|
| Subject group type | Reporting group | Reporting group | Subject analysis set | |
| Number of subjects analysed | 14 ^[5] | 14 ^[6] | 14 ^[7] | |
| Units: mm | | | | |
| arithmetic mean (standard deviation) | | | | |
| Week 2 | 9.7 (± 24.85) | 12.6 (± 29.22) | -2.9 (± 12.64) | |
| Week 4 | 10.0 (± 28.00) | 7.5 (± 31.68) | 2.5 (± 14.07) | |

Notes:

[5] - 4 pts excluded from ESA. Missing data for 1 pt at Week 2 (n=13). At Week 4 n=14.

[6] - 4 pts excluded from ESA. Missing data for 1 pt at Week 2 (n=13). At Week 4 n=14.

[7] - Missing data for 1 pt at Week 2 (n=13). At Week 4 n=14.

Statistical analyses

| | |
|---|---|
| Statistical analysis title | PIC-I CFB: Within-patient Paired t-test, Week 4 |
| Comparison groups | Non-Wound INM-755 v Non-Wound Vehicle |
| Number of subjects included in analysis | 28 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.5178 ^[8] |
| Method | paired t-test |
| Parameter estimate | Mean difference (final values) |
| Point estimate | 2.5 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -5.62 |
| upper limit | 10.62 |
| Variability estimate | Standard deviation |
| Dispersion value | 14.07 |

Notes:

[8] - p-value at Week 2 = 0.4206

Other pre-specified: Plasma Cannabinol Concentration, End of Study

| | |
|---|---|
| End point title | Plasma Cannabinol Concentration, End of Study |
| End point description: | |
| It was optional for patients to provide a single blood sample for analysis at the end of treatment. 14 patients consented to this. Most samples were drawn within 0-2 days after last dose. For 3 patients, the samples were at 5, 7, and 19 days after last dose. Limit of quantitation was 1.0 pg/mL. | |
| End point type | Other pre-specified |

End point timeframe:
Week 4 (End of Study)

| | | | | |
|-------------------------------|------------------------------------|--|--|--|
| End point values | Pharmacokinetic Analysis Set (PKS) | | | |
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 14 | | | |
| Units: pg/mL | | | | |
| median (full range (min-max)) | 4.850 (0.00 to 176.00) | | | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Entire treatment period: From first dose of study treatment until completion of therapy (max 4 weeks), and 1 week additional safety follow-up.

Adverse event reporting additional description:

AEs were collected at weekly visits and recorded as local or systemic.

Local AEs in index areas: treatment-emergent (TE) local AEs were summarised by treatment, severity, association with treatment or dressings.

Other Local AEs (in untreated areas).

Systemic AEs: TE systemic AEs were summarised by severity, association with treatment

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|--------------------|--------|
| Dictionary name | MedDRA |
| Dictionary version | 25.0 |

Reporting groups

| | |
|-----------------------|--|
| Reporting group title | INM-755 Treated Non-wound Index Areas, Local AEs |
|-----------------------|--|

Reporting group description:

This is the group of NW Index Areas treated with INM-755. Each patient with matched pairs of NW Index Areas received both treatments, one area treated with INM-755, the other with Vehicle (randomised, blinded).

| | |
|-----------------------|--|
| Reporting group title | INM-755 Treated Wound Index Areas, Local AEs |
|-----------------------|--|

Reporting group description:

This is the group of Wound Index Areas treated with INM-755. Each patient with matched pairs of Wound Index Areas received both treatments, one area treated with INM-755, the other with Vehicle (randomised, blinded).

| | |
|-----------------------|--|
| Reporting group title | Vehicle Treated Non-wound Index Areas, Local AEs |
|-----------------------|--|

Reporting group description:

This is the group of NW Index Areas treated with Vehicle. Each patient with matched pairs of NW Index Areas received both treatments, one area treated with INM-755, the other with Vehicle (randomised, blinded).

| | |
|-----------------------|--|
| Reporting group title | Vehicle Treated Wound Index Areas, Local AEs |
|-----------------------|--|

Reporting group description:

This is the group of Wound Index Areas treated with Vehicle. Each patient with matched pairs of Wound Index Areas received both treatments, one area treated with INM-755, the other with Vehicle (randomised, blinded).

| | |
|-----------------------|----------------------------|
| Reporting group title | Untreated Areas, Local AEs |
|-----------------------|----------------------------|

Reporting group description:

AEs were categorized as local or systemic. These local areas were not treated. The underlying disease (epidermolysis bullosa) is characterized by many skin lesions.

| | |
|-----------------------|------------------------------------|
| Reporting group title | All Treated Patients, Systemic AEs |
|-----------------------|------------------------------------|

Reporting group description:

All patients received both INM-755 and Vehicle as topical treatments on matched index area pairs. These are the systemic AEs reported, not the AEs that occurred locally at the treated index areas or in other local untreated areas.

| Serious adverse events | INM-755 Treated Non-wound Index Areas, Local AEs | INM-755 Treated Wound Index Areas, Local AEs | Vehicle Treated Non-wound Index Areas, Local AEs |
|---|--|--|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 2 (0.00%) | 0 / 18 (0.00%) |

| | | | |
|---|---|---------------|----------------|
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |
| Infections and infestations | | | |
| Endocarditis | Additional description: Endocarditis after 3 weeks of treatment, assessed as not related to masked study treatment. In the opinion of the Investigator, the event was due to the underlying medical condition of cardiomyopathy. Hospitalised, study treatment interrupted. | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 2 (0.00%) | 0 / 18 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | Vehicle Treated Wound Index Areas, Local AEs | Untreated Areas, Local AEs | All Treated Patients, Systemic AEs |
|---|---|-------------------------------|---------------------------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 19 (0.00%) | 1 / 19 (5.26%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |
| Infections and infestations | | | |
| Endocarditis | Additional description: Endocarditis after 3 weeks of treatment, assessed as not related to masked study treatment. In the opinion of the Investigator, the event was due to the underlying medical condition of cardiomyopathy. Hospitalised, study treatment interrupted. | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 19 (0.00%) | 1 / 19 (5.26%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | INM-755 Treated Non-wound Index Areas, Local AEs | INM-755 Treated Wound Index Areas, Local AEs | Vehicle Treated Non-wound Index Areas, Local AEs |
|---|--|--|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 3 / 18 (16.67%) | 0 / 2 (0.00%) | 2 / 18 (11.11%) |
| Vascular disorders | | | |
| Hypertension | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 2 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nervous system disorders | | | |
| Headache | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 2 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| General disorders and administration site conditions | | | |

| | | | |
|---|----------------------|--------------------|---------------------|
| Pyrexia subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 2 (0.00%) 0 | 0 / 18 (0.00%) 0 |
| Gastrointestinal disorders Anal fissure subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 2 (0.00%) 0 | 0 / 18 (0.00%) 0 |
| Toothache subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 2 (0.00%) 0 | 0 / 18 (0.00%) 0 |
| Reproductive system and breast disorders Dysmenorrhoea subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 2 (0.00%) 0 | 0 / 18 (0.00%) 0 |
| Skin and subcutaneous tissue disorders Blister subjects affected / exposed occurrences (all) | 1 / 18 (5.56%) 1 | 0 / 2 (0.00%) 0 | 0 / 18 (0.00%) 0 |
| Eczema asteatotic subjects affected / exposed occurrences (all) | 1 / 18 (5.56%) 1 | 0 / 2 (0.00%) 0 | 1 / 18 (5.56%) 1 |
| Erythema subjects affected / exposed occurrences (all) | 1 / 18 (5.56%) 1 | 0 / 2 (0.00%) 0 | 1 / 18 (5.56%) 1 |
| Pruritus subjects affected / exposed occurrences (all) | 2 / 18 (11.11%) 2 | 0 / 2 (0.00%) 0 | 1 / 18 (5.56%) 1 |
| Pseudofolliculitis subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 2 (0.00%) 0 | 0 / 18 (0.00%) 0 |
| Skin ulcer subjects affected / exposed occurrences (all) | 0 / 18 (0.00%) 0 | 0 / 2 (0.00%) 0 | 0 / 18 (0.00%) 0 |
| Infections and infestations Endocarditis | | | |

| | | | |
|-----------------------------|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 2 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 2 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| Non-serious adverse events | Vehicle Treated Wound Index Areas, Local AEs | Untreated Areas, Local AEs | All Treated Patients, Systemic AEs |
|---|--|-------------------------------|---------------------------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 3 / 19 (15.79%) | 7 / 19 (36.84%) |
| Vascular disorders | | | |
| Hypertension | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 19 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Nervous system disorders | | | |
| Headache | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 19 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 4 |
| General disorders and administration site conditions | | | |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 19 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Gastrointestinal disorders | | | |
| Anal fissure | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 19 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Toothache | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 19 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Reproductive system and breast disorders | | | |
| Dysmenorrhoea | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 19 (0.00%) | 2 / 19 (10.53%) |
| occurrences (all) | 0 | 0 | 2 |
| Skin and subcutaneous tissue disorders | | | |
| Blister | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 1 / 19 (5.26%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |

| | | | |
|-----------------------------|---------------|----------------|----------------|
| Eczema asteatotic | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 19 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Erythema | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 19 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pruritus | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 19 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pseudofolliculitis | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 1 / 19 (5.26%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Skin ulcer | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 1 / 19 (5.26%) | 0 / 19 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Infections and infestations | | | |
| Endocarditis | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 19 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 19 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all) | 0 | 0 | 1 |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported